Note: Ingredients listed on restricted chemical lists
EC/CAS
680-598-3/70142-34-6
Name of the chemical
polyethyleneglycol-30 dipolyhydroxystearate
Concentration
>=2,5-<10
EC/CAS
204-881-4/128-37-0
Name of the chemical
2,6-di-tert-butyl-p-cresol
Concentration
=0,1-<0,25
General Information
Version
3.2
Revision date
2023-02-23
Product name
Nexgard Spectra Chewables
Product Synonyms
Afoxolaner 1.9% / Milbemycin Oxime 0.4% w/w Chewable Tablets, Nexgard Spectra® DOG
1.2.1 Relevant identified uses
Veterinary product
1.2.2. Uses advised against
Safety Data Sheet only for the professional user., For veteri- on use nary use only, Refer to the product insert for complete instruc- tions on usage
Emergency telephone
+498007790900, +1 703-527-3887, +49800 1817059
Icons in SDS
Company Information
company name
Boehringer Ing. Pharma GmbH & Co. KG
e-mail address of the competent person responsible for the Safety Data Sheet
EHS-Services@Boehringer-Ingelheim.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H317, H412
Hazard statements
Code
Statements
H317
May cause an allergic skin reaction
Section 2
SECTION 2: Hazards identification
Regulation (EC) No. 1272/2008 Classification of the substance or mixture
Signal word
Warning
Hazard statements
H317 May cause an allergic skin reaction. H412 Harmful to aquatic life with long lasting effects.
Prevention
P261 Avoid breathing dust. P273 Avoid release to the environment. P280 Wear protective gloves.
Response
P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention. P362 + P364 Take off contaminated clothing and wash it before reuse.
Disposal
P501 Dispose of contents/ container to an approved waste disposal plant.
Hazardous Ingredients
Octadecanoic acid, 12-hydroxy-, polymer with alpha-hydro-omega-hydroxypoly(oxy-1,2- ethanediyl) (Average MW ca. = 1070 g/mol, EO = 16,6 mol)
2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumula- tive and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
ECOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regu- lation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
TOXICOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher. This drug is not subject to the labelling requirements under the Globally Harmonized System (GHS) The pharmacological effect of the medicament has to be considered (see package leaflet).
2.1 Classification of the substance or mixture
Classification (REGULATION (EC) No 1272/2008) Skin sensitisation, Category 1 H317: May cause an allergic skin reaction. Long-term (chronic) aquatic hazard, Cat- H412: Harmful to aquatic life with long lasting ef- egory 3 fects.
